ANUH PHARMA 2023-24 Annual Report Analysis

Thu, 1 Aug

ANUH PHARMA has announced its results for the year ended March 2024. Let us have a look at the detailed performance review of the company during FY23-24.

ANUH PHARMA Income Statement Analysis

• Operating income during the year rose 22.7% on a year-on-year (YoY) basis.
• The company's operating profit increased by 46.2% YoY during the fiscal. Operating profit margins witnessed a fall and down at 11.7% in FY24 as against 9.8% in FY23.
• Depreciation charges decreased by 11.5% and finance costs increased by 28.3% YoY, respectively.
• Other income grew by 97.8% YoY.
• Net profit for the year grew by 66.0% YoY.
• Net profit margins during the year grew from 6.9% in FY23 to 9.3% in FY24.

ANUH PHARMA Income Statement 2023-24

No. of Mths Year Ending		12 Mar-23*	12 Mar-24*	% Change
Net Sales	Rs m	5,275	6,470	22.7%
Other income	Rs m	61	121	97.8%
Total Revenues	Rs m	5,336	6,591	23.5%
Gross profit	Rs m	518	758	46.2%
Depreciation	Rs m	97	86	-11.5%
Interest	Rs m	7	10	28.3%
Profit before tax	Rs m	475	783	65.0%
Tax	Rs m	113	183	61.7%
Profit after tax	Rs m	362	601	66.0%
Gross profit margin	%	9.8	11.7
Effective tax rate	%	23.8	23.3
Net profit margin	%	6.9	9.3

Must See: These Segments are Witnessing Incredible Growth with Modi's Push

ANUH PHARMA Balance Sheet Analysis

• The company's current liabilities during FY24 down at Rs 2 billion as compared to Rs 2 billion in FY23, thereby witnessing an decrease of -5.4%.
• Current assets rose 9% and stood at Rs 3 billion, while fixed assets rose 13% and stood at Rs 1 billion in FY24.
• Overall, the total assets and liabilities for FY24 stood at Rs 4 billion as against Rs 4 billion during FY23, thereby witnessing a growth of 10%.

ANUH PHARMA Balance Sheet as on March 2024

No. of Mths Year Ending		12 Mar-23*	12 Mar-24*	% Change
Networth	Rs m	2,412	2,912	20.7
Current Liabilities	Rs m	1,613	1,527	-5.4
Long-term Debt	Rs m	0	0	0.0
Total Liabilities	Rs m	4,042	4,453	10.2
Current assets	Rs m	3,076	3,362	9.3
Fixed Assets	Rs m	966	1,091	12.9
Total Assets	Rs m	4,042	4,453	10.2

ANUH PHARMA Cash Flow Statement Analysis

• ANUH PHARMA's cash flow from operating activities (CFO) during FY24 stood at Rs 129 million on a YoY basis.
• Cash flow from investing activities (CFI) during FY24 stood at Rs 9 million on a YoY basis.
• Cash flow from financial activities (CFF) during FY24 stood at Rs -86 million, an improvement of 30% on a YoY basis.
• Overall, net cash flows for the company during FY24 stood at Rs 53 million from the Rs -19 million net cash flows seen during FY23.

ANUH PHARMA Cash Flow Statement 2023-24

Particulars	No. of months	12	12	% Change
	Year Ending	Mar-23	Mar-24
Cash Flow from Operating Activities	Rs m	539	129	-76.0%
Cash Flow from Investing Activities	Rs m	-435	9	-
Cash Flow from Financing Activities	Rs m	-123	-86	-
Net Cash Flow	Rs m	-19	53	-

Current Valuations for ANUH PHARMA

• The trailing twelve-month earnings per share (EPS) of the company stands at Rs 12.0, an improvement from the EPS of Rs 7.2 recorded last year.
• The price to earnings (P/E) ratio, at the current price of Rs 241.6, stands at 20.2 times its trailing twelve months earnings.
• The price to book value (P/BV) ratio at current price levels stands at 4.2 times, while the price to sales ratio stands at 1.9 times.
• The company's price to cash flow (P/CF) ratio stood at 12.4 times its end-of-year operating cash flow earnings.

Per Share Data/Valuations

No. of Mths Year Ending		12 Mar-23*	12 Mar-24*
Sales per share (Unadj.)	Rs	105.3	129.1
TTM Earnings per share	Rs	7.2	12.0
Diluted earnings per share	Rs	7.2	12.0
Price to Cash Flow	x	8.7	12.4
TTM P/E ratio	x	11.0	20.2
Price / Book Value ratio	x	1.9	2.9
Market Cap	Rs m	4,683	8,513
Dividends per share (Unadj.)	Rs	2.0	2.5

Ratio Analysis for ANUH PHARMA

• Solvency Ratios

Current Ratio: The company's current ratio improved and stood at 2.2x during FY24, from 1.9x during FY23. The current ratio measures the company's ability to pay short-term and long-term obligations.

Interest Coverage Ratio: The company's interest coverage ratio improved and stood at 82.8x during FY24, from 64.6x during FY23. The interest coverage ratio of a company states how easily a company can pay its interest expense on outstanding debt. A higher ratio is preferable.

• Profitability Ratios

Return on Equity (ROE): The ROE for the company improved and stood at 20.6% during FY24, from 15.0% during FY24. The ROE measures the ability of a firm to generate profits from its shareholders capital in the company.

Return on Capital Employed (ROCE): The ROCE for the company improved and stood at 27.2% during FY24, from 20.0% during FY23. The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company.

Return on Assets (ROA): The ROA of the company improved and stood at 13.7% during FY24, from 9.1% during FY23. The ROA measures how efficiently the company uses its assets to generate earnings.

Key Ratio Analysis

No. of Mths Year Ending		12 Mar-23*	12 Mar-24*
Current ratio	x	1.9	2.2
Debtors’ Days	Days	1,185	1,072
Interest coverage	x	64.6	82.8
Debt to equity ratio	x	0.0	0.0
Return on assets	%	9.1	13.7
Return on equity	%	15.0	20.6
Return on capital employed	%	20.0	27.2

To see how ANUH PHARMA has performed over the last 5 years, please visit here.

ANUH PHARMA Share Price Performance

Over the last one year, ANUH PHARMA share price has moved up from Rs 128.3 to Rs 241.6, registering a gain of Rs 113.3 or around 88.3%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 40,656.7 (up 0.3%). Over the last one year it has moved up from 27,644.7 to 40,656.7, a gain of 13,012 points (up 47.1%).

Overall, the S&P BSE SENSEX is up 23.1% over the year.

(To know more, check out historical annual results for ANUH PHARMA and quarterly results for ANUH PHARMA)